Search
                    Schizophrenia Clinical Trials
A listing of 84  Schizophrenia  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 84
        
                There are currently 84 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Schizophrenia participants are California, Florida, Texas and New York.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
                                
            
            
        Recruiting
                            
            
                Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.             
        
        
    Gender:
                ALL
            Ages:
                Between 15 years and 35 years
            Trial Updated:
                10/28/2024
            
            Locations: Harding Hospital, Columbus, Ohio         
        
        
            Conditions: Psychosis, Schizophrenia, First-episode Psychosis
        
            
        
    
                
                                    Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
                                
            
            
        Recruiting
                            
            
                Magnetic Resonance Imaging (MRI) unlike X-rays and CT-scans does not use radiation to create a picture. MRI use as the name implies, magnetism to create pictures with excellent anatomical resolution. Functional MRIs are diagnostic tests that allow doctors to not only view anatomy, but physiology and function. It is for these reasons that MRIs are excellent methods for studying the brain.
In this study, researchers will use MRI to assess brain anatomy and function in X and Y chromosome variation...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 3 years and 120 years
            Trial Updated:
                08/13/2025
            
            Locations: National Institutes of Health Clinical Center, Bethesda, Maryland         
        
        
            Conditions: Schizophrenia, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder
        
            
        
    
                
                                    Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
                                
            
            
        Recruiting
                            
            
                This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with Bipolar Disorders, Schizophrenia, Schizoaffective, and Schizophreniform disorders and correlate them with clinician-assessed ratings.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/08/2025
            
            Locations: BioXcel Clinical Research Site 103, Chino, California  +4 locations         
        
        
            Conditions: Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation
        
            
        
    
                
                                    Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine
                                
            
            
        Recruiting
                            
            
                In this study, the investigators will examine whether a type of repetitive transcranial magnetic stimulation called accelerated intermittent theta burst stimulation (iTBS) can augment neurocognition in individuals who receive treatment with clozapine. Following a baseline evaluation and magnetic resonance imaging (MRI), participants will undergo a session of iTBS +MRI and session of sham delivery + MRI. The order for these sessions will be blinded and randomized. The investigators predict that a...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 50 years
            Trial Updated:
                08/06/2025
            
            Locations: UPMC Western Psychiatric Hospital/University of Pittsburgh, Pittsburgh, Pennsylvania         
        
        
            Conditions: Schizophrenia, Schizoaffective Disorder
        
            
        
    
                
                                    NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
                                
            
            
        Recruiting
                            
            
                This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                08/06/2025
            
            Locations: Neurocrine Clinical Site, Pico Rivera, California  +1 locations         
        
        
            Conditions: Schizophrenia
        
            
        
    
                
                                    A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
                                
            
            
        Recruiting
                            
            
                ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis.
The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syn...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 64 years
            Trial Updated:
                08/04/2025
            
            Locations: Clinical Site, Little Rock, Arkansas  +24 locations         
        
        
            Conditions: Schizophrenia
        
            
        
    
                
                                    Decision-Making in Schizophrenia: A Combined Neuroimaging and Experience Sampling Study
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to learn if attention and ways of thinking impact decision-making and brain processes related to decision-making in people with schizophrenia or schizoaffective disorder relative to people without either condition. It will also learn how brain functioning during decision-making relates to real-world decisions made during daily life. The main questions it aims to answer are:
* Does paying attention to specific information impact decision-making and brain proces...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 45 years
            Trial Updated:
                08/01/2025
            
            Locations: Center for Advanced Human Brain Imaging Research, Piscataway, New Jersey         
        
        
            Conditions: Schizophrenia, Schizoaffective Disorder, Control Subjects
        
            
        
    
                
                                    Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
                                
            
            
        Recruiting
                            
            
                To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine             
        
        
    Gender:
                ALL
            Ages:
                Between 10 years and 17 years
            Trial Updated:
                07/29/2025
            
            Locations: Alkermes Investigator Site, Dothan, Alabama  +46 locations         
        
        
            Conditions: Schizophrenia, Bipolar I Disorder
        
            
        
    
                
                                    NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
                                
            
            
        Recruiting
                            
            
                The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                07/29/2025
            
            Locations: Neurocrine Clinical Site, Little Rock, Arkansas  +10 locations         
        
        
            Conditions: Schizophrenia
        
            
        
    
                
                                    Luteolin for the Treatment of People With Schizophrenia
                                
            
            
        Recruiting
                            
            
                Luteolin is a natural product found in foods such as celery, green pepper, parsley, and chamomile tea. It has been found to have anti-cancer, anti-oxidant, and anti-inflammatory properties. The purpose of this study is to determine if luteolin helps improve symptoms of schizophrenia.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 60 years
            Trial Updated:
                07/28/2025
            
            Locations: University of California, Los Angeles, Los Angeles, California  +1 locations         
        
        
            Conditions: Schizophrenia, Schizoaffective Disorder
        
            
        
    
                
                                    Song-making In a Group (SING)
                                
            
            
        Recruiting
                            
            
                The overarching aim of the proposed work is to align a promising treatment lead - Musical Intervention (MI) - with a promising mechanistic account of psychosis - Predictive Processing. This protocol focuses on the R33 phase, to optimize its administration (Is active participation more effective than passive listening? Does creation of new music help more than performing others' creations?). By tracking the interrelation between symptom mechanisms and MI, the investigators can use those metrics t...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                07/25/2025
            
            Locations: Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut         
        
        
            Conditions: Schizophrenia
        
            
        
    
                
                                    Study of SPG302 in Adults With Schizophrenia
                                
            
            
        Recruiting
                            
            
                This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                07/23/2025
            
            Locations: CenExel CNS, Garden Grove, California  +2 locations         
        
        
            Conditions: Schizophrenia
        
            
        
    1 - 12 of 84
            